Shanghai Henlius Biotech Inc Class H 02696
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- HK$22.85
- Day Range
- HK$22.55–22.70
- 52-Week Range
- HK$9.60–23.45
- Bid/Ask
- HK$22.60 / HK$22.65
- Market Cap
- HK$12.28 Bil
- Volume/Avg
- 399,800 / 457,247
Key Statistics
- Price/Earnings (Normalized)
- 15.92
- Price/Sales
- 2.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 3,546
- Website
- https://www.henlius.com
Comparables
Valuation
Metric
|
02696
|
4157
|
688062
|
---|---|---|---|
Price/Earnings (Normalized) | 15.92 | 355.04 | — |
Price/Book Value | 4.43 | 9.07 | 5.09 |
Price/Sales | 2.00 | 73.86 | 71.82 |
Price/Cash Flow | 10.23 | 180.19 | — |
Price/Earnings
02696
4157
688062
Financial Strength
Metric
|
02696
|
4157
|
688062
|
---|---|---|---|
Quick Ratio | 0.32 | 19.37 | 1.53 |
Current Ratio | 0.49 | 20.34 | 1.78 |
Interest Coverage | 6.49 | 136.44 | −32.55 |
Quick Ratio
02696
4157
688062
Profitability
Metric
|
02696
|
4157
|
688062
|
---|---|---|---|
Return on Assets (Normalized) | 7.67% | 4.77% | −24.26% |
Return on Equity (Normalized) | 33.96% | 5.29% | −41.90% |
Return on Invested Capital (Normalized) | 12.87% | 3.05% | −26.98% |
Return on Assets
02696
4157
688062
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk AS ADR
NVO
| Ppzpxgpxg | Kxlh | $512.4 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Mldmzzcx | Pzvdmg | $117.5 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Pcysdwbr | Jjfqdty | $111.6 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Kqnwtwf | Bfbkl | $34.4 Bil | |||
argenx SE ADR
ARGX
| Shfrgqcx | Krvyl | $31.7 Bil | |||
BioNTech SE ADR
BNTX
| Yxjywjbt | Qwc | $29.2 Bil | |||
Moderna Inc
MRNA
| Pgmncyql | Xjjs | $23.1 Bil | |||
United Therapeutics Corp
UTHR
| Qwrqnbb | Bmmkw | $15.8 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Sdwcqqwt | Yphrs | $13.2 Bil | |||
Incyte Corp
INCY
| Gzbtslm | Brfhhbl | $13.0 Bil |